About Lyell Immunopharma
Lyell Immunopharma is a company based in San Francisco (United States) founded in 2018 by Rick Klausner.. Lyell Immunopharma has raised $493 million across 3 funding rounds from investors including GSK and Sahsen Ventures. The company has 300 employees as of December 31, 2024. Lyell Immunopharma has completed 1 acquisition, including ImmPACT-Bio. Lyell Immunopharma offers products and services including LYL314 and CAR T-cell Therapies. Lyell Immunopharma operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Hummingbird Bioscience and Autolus, among others.
- Headquarter San Francisco, United States
- Employees 300 as on 31 Dec, 2024
- Founders Rick Klausner
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lyell Immunopharma, Inc.
-
Annual Revenue
$61 K-53.08as on Dec 31, 2024
-
Net Profit
$-342.99 M-46.18as on Dec 31, 2024
-
EBITDA
$-204.26 M11.38as on Dec 31, 2024
-
Total Equity Funding
$493 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Jul 25, 2025
-
Investors
GSK
& 1 more
-
Employee Count
300
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lyell Immunopharma
Lyell Immunopharma is a publicly listed company on the NASDAQ with ticker symbol LYEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lyell Immunopharma
Lyell Immunopharma offers a comprehensive portfolio of products and services, including LYL314 and CAR T-cell Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets relapsed large B-cell lymphoma through advanced cell therapies
Develops treatments for solid tumors and hematologic malignancies
Unlock access to complete
Unlock access to complete
Funding Insights of Lyell Immunopharma
Lyell Immunopharma has successfully raised a total of $493M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $100.0M
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Post-IPO - Lyell Immunopharma | Valuation |
investors |
|
| Mar, 2020 | Amount | Series C - Lyell Immunopharma | Valuation | GSK |
|
| Jun, 2018 | Amount | Seed - Lyell Immunopharma | Valuation | Sahsen Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lyell Immunopharma
Lyell Immunopharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include GSK and Sahsen Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in multiple sectors are made by Sahsen Ventures.
|
Founded Year | Domain | Location | |
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lyell Immunopharma
Lyell Immunopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ImmPACT-Bio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biotechnology research and development are conducted in Israel.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Lyell Immunopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lyell Immunopharma Comparisons
Competitors of Lyell Immunopharma
Lyell Immunopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Hummingbird Bioscience and Autolus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lyell Immunopharma
Frequently Asked Questions about Lyell Immunopharma
When was Lyell Immunopharma founded?
Lyell Immunopharma was founded in 2018.
Where is Lyell Immunopharma located?
Lyell Immunopharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Lyell Immunopharma?
Rick Klausner is the current CEO of Lyell Immunopharma. They have also founded this company.
Is Lyell Immunopharma a funded company?
Lyell Immunopharma is a funded company, having raised a total of $493M across 3 funding rounds to date.
How many employees does Lyell Immunopharma have?
As of Dec 31, 2024, the latest employee count at Lyell Immunopharma is 300.
What is the annual revenue of Lyell Immunopharma?
Annual revenue of Lyell Immunopharma is $61K as on Dec 31, 2024.
What does Lyell Immunopharma do?
Founded in 2018 and based in San Francisco, United States, the biotechnology firm focuses on oncology. CAR-T therapies are advanced for treating ROR1-positive non-small cell lung cancer and triple-negative breast cancer through the lead program LYL797. An autologous TIL therapy, LYL845, is pursued for multiple solid tumors. Operations center on clinical development of these immunotherapies to address unmet needs in cancer care.
Who are the top competitors of Lyell Immunopharma?
Lyell Immunopharma's top competitors include Hummingbird Bioscience, Juno Therapeutics and Immatics.
What products or services does Lyell Immunopharma offer?
Lyell Immunopharma offers LYL314 and CAR T-cell Therapies.
Is Lyell Immunopharma publicly traded?
Yes, Lyell Immunopharma is publicly traded on NASDAQ under the ticker symbol LYEL.
How many acquisitions has Lyell Immunopharma made?
Lyell Immunopharma has made 1 acquisition, including ImmPACT-Bio.
Who are Lyell Immunopharma's investors?
Lyell Immunopharma has 2 investors. Key investors include GSK, and Sahsen Ventures.
What is Lyell Immunopharma's ticker symbol?
The ticker symbol of Lyell Immunopharma is LYEL on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.